Merck Animal Health Gains FDA Approval for 12-Month Asian Longhorned and Gulf Coast Tick Control
Merck Animal Health secured FDA approval to expand BRAVECTO QUANTUM’s label for 12-month treatment and control of Asian longhorned and Gulf Coast ticks in dogs via a single veterinary injection. The expanded indication complements existing coverage against black-legged, American dog and brown dog ticks, reinforcing Merck’s leadership in extended-duration parasiticide solutions and supporting potential revenue growth in its animal health segment.
1. FDA Label Expansion for Tick Control
Merck Animal Health’s BRAVECTO QUANTUM received FDA approval to expand its label for the 12-month treatment and control of Asian longhorned and Gulf Coast ticks in dogs following a single veterinarian-administered injection.
2. Comprehensive Protection and Market Implications
The updated indication complements existing 12-month protection against black-legged, American dog and brown dog ticks and 8-month coverage for lone star ticks, reinforcing BRAVECTO QUANTUM’s position as the longest-duration injectable parasiticide and addressing the geographic spread of clinically important tick species.
3. Strategic Significance for Merck Animal Health
The expanded label underscores Merck Animal Health’s leadership in extended-duration parasiticides and is poised to boost compliance and segment revenues by offering veterinarians a convenient, once-yearly solution against an expanding parasite landscape.